RGC

Business Context and Reporting Period

Company: Regencell Bioscience Holdings Ltd (RGC)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended June 30, 2024
Business Overview: An early-stage bioscience company incorporated in the Cayman Islands with operations in Hong Kong. The company focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) formulae for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). The company has not yet generated revenue from product sales and relies on a strategic partnership with Mr. Sik-Kee Au (the "TCM Practitioner") for its proprietary formulae.

Key Financial Metrics

Note: The filing text does not provide specific data for "2023 Q4" as a standalone quarter; the financial data presented covers the full fiscal year ended June 30, 2024.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately 28% (from $6.06 million to $4.36 million) compared to the prior fiscal year.
• Expense Reductions: Total operating expenses declined by 24% ($1.54 million).
  • General & Administrative (G&A): Decreased by 20% ($0.88 million), driven by lower share-based compensation, reduced professional fees, and lower payroll/bonuses.
  • Research & Development (R&D): Decreased by 33% ($0.52 million), attributed to lower share-based compensation, reduced bonuses, and decreased costs for TCM formulae materials and rental expenses.
  • Selling & Marketing: Decreased by 52% ($0.14 million) due to reduced marketing initiative expenses.
• Increased Other Income: Other income, net, increased by 77% (from $0.21 million to $0.37 million), primarily due to higher interest income from short-term investments and bank deposits.
• Liquidity Position: Cash and short-term investments decreased from $11.6 million to $8.0 million, reflecting continued operating cash burn, though the company maintains sufficient liquidity for at least the next 12 months.

Guidance, Outlook, Risks, and Contingencies

Outlook and Management Commentary

• Product Development: The company is conducting a second efficacy trial using three standardized TCM formulae candidates for mild, moderate, and severe ADHD/ASD. Interim results suggest reduced symptom severity, but the company has not yet applied for regulatory approval.
• Commercialization: No revenue is expected until regulatory approval is obtained and products are commercialized in Hong Kong. The company plans to set up centralized production facilities upon successful trial completion.
• Capital Needs: The company anticipates incurring additional losses before realizing revenue and may require additional financing to sustain operations and fund future expansion.

Material Risks

• Going Concern: The company has incurred recurring losses since inception. While current cash reserves are deemed sufficient for 12 months, there is uncertainty regarding the ability to continue as a going concern without additional financing.
• Internal Controls: Management identified three material weaknesses in internal control over financial reporting:
  • Lack of sufficient skilled staff with U.S. GAAP and SEC reporting knowledge.
  • Lack of an internal audit function.
  • Lack of segregation of duties for key functions.
• Regulatory Approval: Success depends on obtaining regulatory approval from the Hong Kong Chinese Medicines Board. There is no assurance that the TCM formulae will be approved or that the company can commercialize them.
• Key Personnel Dependence: The business is wholly dependent on the TCM Practitioner (Mr. Sik-Kee Au) for research and development. Loss of this partnership would materially harm the business.
• PFIC Status: The company believes it was a Passive Foreign Investment Company (PFIC) for the taxable year ended June 30, 2024, which could result in adverse U.S. federal income tax consequences for U.S. holders.

Key Facts for Investor Verification

• Revenue Status: Verify that the company has generated zero revenue to date and has no approved products on the market.
• Cash Runway: Confirm the current cash balance ($8.0 million as of June 30, 2024) against the burn rate to assess the timeline for potential dilution or financing needs.
• Internal Control Remediation: Monitor progress on remediation of the three identified material weaknesses in internal controls, as failure to address these could lead to restatements or delisting.
• Regulatory Milestones: Track the status of the second efficacy trial and the timeline for filing for regulatory approval with the Hong Kong Chinese Medicines Board.
• Related Party Transactions: Review the ongoing financial relationship and dependency on the TCM Practitioner and related entities (e.g., Regeneration Company Limited) for R&D costs.